Daniel D. Rhoads

6.7k total citations · 1 hit paper
97 papers, 4.4k citations indexed

About

Daniel D. Rhoads is a scholar working on Infectious Diseases, Molecular Biology and Clinical Biochemistry. According to data from OpenAlex, Daniel D. Rhoads has authored 97 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 25 papers in Molecular Biology and 24 papers in Clinical Biochemistry. Recurrent topics in Daniel D. Rhoads's work include Bacterial Identification and Susceptibility Testing (24 papers), Antibiotic Resistance in Bacteria (14 papers) and Bacterial biofilms and quorum sensing (13 papers). Daniel D. Rhoads is often cited by papers focused on Bacterial Identification and Susceptibility Testing (24 papers), Antibiotic Resistance in Bacteria (14 papers) and Bacterial biofilms and quorum sensing (13 papers). Daniel D. Rhoads collaborates with scholars based in United States, Spain and Canada. Daniel D. Rhoads's co-authors include Randall D. Wolcott, Scot E. Dowd, Yan Sun, Garth A. James, Patrick R. Secor, Yan V. Sun, Philip C. Noble, Hugh S. Tullós, Randy Wolcott and Loren S. Ward and has published in prestigious journals such as PLoS ONE, Neurology and Clinical Microbiology Reviews.

In The Last Decade

Daniel D. Rhoads

89 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Survey of bacterial diversity in chronic wounds using Pyrosequencing, DGGE, and full ribosome shotgun sequencing

2008 612 citations Daniel D. Rhoads et al. profile →

Peers

Countries citing papers authored by Daniel D. Rhoads

Since Specialization

Citations

This map shows the geographic impact of Daniel D. Rhoads's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel D. Rhoads with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel D. Rhoads more than expected).

Fields of papers citing papers by Daniel D. Rhoads

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel D. Rhoads. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel D. Rhoads. The network helps show where Daniel D. Rhoads may publish in the future.

Co-authorship network of co-authors of Daniel D. Rhoads

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel D. Rhoads. A scholar is included among the top collaborators of Daniel D. Rhoads based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel D. Rhoads. Daniel D. Rhoads is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Emerging technologies for rapid phenotypic antimicrobial susceptibility testing of clinical isolates of bacteria 2025 ·Journal of Clinical Microbiology ·(unknown), (unknown), Daniel D. Rhoads	0
2	Urinalysis is predictive for absence of urinary tract infection in men with and without catheters 2024 ·Neurourology and Urodynamics ·Paul Oh, Kevin C. Lewis, Daniel A. Shoskes, Sandip P. Vasavada, Howard B. Goldman, Hadley Wood, Daniel D. Rhoads, Glenn T. Werneburg	2
3	A molecular analysis of meropenem–vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae 2024 ·Antimicrobial Agents and Chemotherapy ·Mohamad Yasmin, Steven H. Marshall, Liang Chen, Daniel D. Rhoads, Michael R. Jacobs, Laura J. Rojas, Federico Pérez, Andrea M. Hujer, Kristine M. Hujer, David van Duin, Vance G. Fowler, Henry F. Chambers, Barry N. Kreiswirth, Robert A. Bonomo, (unknown)	0
4	ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten 2024 ·Antimicrobial Agents and Chemotherapy ·Michael R. Jacobs, Caryn E. Good, Ayman M. Abdelhamed, Andrew R Mack, Christopher R. Bethel, Steven H. Marshall, Andrea M. Hujer, (unknown), Robin Patel, David van Duin, Vance G. Fowler, Daniel D. Rhoads, David A. Six, Greg Moeck, Tsuyoshi Uehara, Krisztina M. Papp‐Wallace, Robert A. Bonomo	0
5	ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime 2024 ·Antimicrobial Agents and Chemotherapy ·Michael R. Jacobs, Ayman M. Abdelhamed, Caryn E. Good, Andrew R Mack, Christopher R. Bethel, Steven H. Marshall, Andrea M. Hujer, Kristine M. Hujer, Robin Patel, David van Duin, Vance G. Fowler, Daniel D. Rhoads, David A. Six, Greg Moeck, Tsuyoshi Uehara, Krisztina M. Papp‐Wallace, Robert A. Bonomo	6
6	Trends and drivers of pedestrian mobility in Barcelona: A fine-grained study across its commercial tissue 2024 ·Cities ·Clément Rames, Daniel D. Rhoads, (unknown), Sergi Lozano, Javier Borge‐Holthoefer, Albert Solé‐Ribalta	0
7	Urinalysis Exhibits Excellent Predictive Capacity for the Absence of Urinary Tract Infection 2023 ·Urology ·Glenn T. Werneburg, Kevin C. Lewis, Sandip P. Vasavada, Hadley Wood, Howard B. Goldman, Daniel A. Shoskes, (unknown), Daniel D. Rhoads	5
8	False positive congenital cytomegalovirus saliva screening results with an FDA-approved assay at two institutions 2023 ·Journal of Clinical Virology ·(unknown), Frank Esper, (unknown), Mary Kathryn Doud, (unknown), (unknown), (unknown), Romney M. Humphries, Daniel D. Rhoads, David C. Gaston, Hannah Wang	4
9	Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience 2022 ·Microbiology Spectrum ·(unknown), (unknown), Zheng Jin Tu, Joy Nakitandwe, (unknown), David Bosler, Stephanie L. Mitchell, Michael J. Loeffelholz, Daniel D. Rhoads	3
10	Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates 2022 ·Journal of Clinical Microbiology ·Patricia J. Simner, Kimberlee A. Musser, Kara Mitchell, Mark G. Wise, Shawna Lewis, Rebecca Yee, Yehudit Bergman, Caryn E. Good, Ayman M. Abdelhamed, Henry Li, (unknown), (unknown), (unknown), (unknown), G. Terrance Walker, Michael R. Jacobs, Daniel D. Rhoads	6
11	Raising the Bar: Improving Antimicrobial Resistance Detection by Clinical Laboratories by Ensuring Use of Current Breakpoints 2022 ·Open Forum Infectious Diseases ·Patricia J. Simner, Carol A. Rauch, Isabella W. Martin, Kaede V. Sullivan, Daniel D. Rhoads, (unknown), Rosemary C. She, Rhona J. Souers, Christina Wojewoda, Romney M. Humphries	24
12	Tailored Treatment Based on Helicobacter pylori Genetic Markers of Resistance Is Associated With Higher Eradication Success 2022 ·The American Journal of Gastroenterology ·Linda C. Cummings, (unknown), (unknown), Lisa M. Stempak, Daniel D. Rhoads, Navid Sadri	5
13	Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status 2021 ·Journal of Clinical Microbiology ·David R. Peaper, Daniel D. Rhoads, Kaede V. Sullivan, Marc Roger Couturier, Romney M. Humphries, Isabella W. Martin, Frederick S. Nolte, Marie‐Claire Rowlinson, Rosemary C. She, Patricia J. Simner, Elitza S. Theel, Christina Wojewoda	6
14	Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document 2021 ·Journal of Clinical Microbiology ·Alexander L. Greninger, Jennifer Dien Bard, Robert C. Colgrove, Erin H. Graf, Kimberly E. Hanson, Mary K. Hayden, Romney M. Humphries, Christopher F. Lowe, Melissa B. Miller, Dylan R. Pillai, Daniel D. Rhoads, Joseph D. Yao, (unknown)	6
15	Specificity of SARS-CoV-2 Real-Time PCR Improved by Deep Learning Analysis 2021 ·Journal of Clinical Microbiology ·(unknown), (unknown), (unknown), Daniel D. Rhoads, Navid Sadri	11
16	Teleclinical Microbiology: An Innovative Approach to Providing Web-Enabled Diagnostic Laboratory Services in Syria 2021 ·American Journal of Clinical Pathology ·Nabil Karah, Konstantinos Antypas, (unknown), (unknown), Rayane Rafei, Louis‐Patrick Haraoui, Wael Elamin, Monzer Hamzé, Aula Abbara, Daniel D. Rhoads, Liron Pantanowitz, Bernt Eric Uhlin	6
17	Deep Convolutional Neural Networks Implementation for the Analysis of Urine Culture 2021 ·Clinical Chemistry ·(unknown), Eric M. Ransom, (unknown), Carey‐Ann D. Burnham, Daniel D. Rhoads, Navid Sadri	15
18	Understanding, Verifying, and Implementing Emergency Use Authorization Molecular Diagnostics for the Detection of SARS-CoV-2 RNA 2020 ·Journal of Clinical Microbiology ·Stephanie L. Mitchell, Kirsten St. George, Daniel D. Rhoads, Susan M. Butler‐Wu, (unknown), (unknown), Melissa B. Miller	45
19	Helicobacter pylori Mutations Detected by Next-Generation Sequencing in Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Specimens Are Associated with Treatment Failure 2019 ·Journal of Clinical Microbiology ·Behtash Ghazi Nezami, (unknown), (unknown), Daniel D. Rhoads, Navid Sadri	46
20	The cytopathology of Actinomyces, Nocardia, and their mimickers 2017 ·Diagnostic Cytopathology ·Kelsey McHugh, Charles D. Sturgis, Gary W. Procop, Daniel D. Rhoads	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact